Chandigarh, January 5, 2026 – Nectar Lifesciences Limited (NECLIFE) has entered clear oversubscription territory in its ongoing share buyback, with total bids reaching 1.30 times the offer size as of the close of trading on January 2, 2026, driven by strong participation from individual investors and corporates.
The company is executing a fixed-price buyback of up to 3 crore equity shares at ₹27 per share, with the offer remaining open until January 6, 2026.
Buyback Snapshot
| Particulars | Details |
|---|---|
| Company Name | Nectar Lifesciences Limited |
| Symbol | NECLIFE |
| Series | BB |
| Offer Type | Buyback |
| Issue Type | Fixed Price |
| Offer Price | ₹27 per equity share |
| Face Value | ₹1 |
| Issue Size | 3,00,00,000 equity shares |
| Offer Period | December 31, 2025 – January 6, 2026 |
Subscription Status
(As on January 2, 2026 | 4:00 p.m.)| Category | Shares Bid |
|---|---|
| Qualified Institutional Buyers (QIBs) | 4,74,400 |
| Non-Institutional Investors | 1,66,21,772 |
| Individual Investors | 2,19,08,965 |
| Total | 3,90,05,137 |
Segment-wise Participation
Retail investors led the book, bidding for 2.19 crore shares, underscoring strong interest from individual shareholders as the buyback gained momentum through the session.Corporate participation under the non-institutional investor category also strengthened, with bids for 1.66 crore shares, contributing materially to the oversubscription.
QIB participation remained modest, with bids for 4.74 lakh shares, broadly in line with earlier trends.
Price-wise Order Book
| Offer Price (₹) | No. of Orders | Demat Quantity | Physical Quantity | Total Quantity |
|---|---|---|---|---|
| 27.00 | 6,116 | 3,90,05,137 | – | 3,90,05,137 |
About the Company
Nectar Lifesciences Limited is a listed company that completed the divestment of its pharmaceutical operating businesses in 2025. The company is currently focused on capital optimisation and evaluating new strategic opportunities, with the ongoing buyback aimed at returning surplus funds to shareholders and streamlining its equity structure.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.